摘要
李秀林:在世界经济一体化潮流中,中国民族医药正处于发展决策的关键阶段。医药行业是技术密集型、知识密集型行业,发展速度很快,受世界经济的影响尤为明显。中国即将加入WTO,我们如何与国际企业进行竞争,实践证明,我们历史悠久的民族医药在临床疗效等方面具有一定优势,但由于文化差异和研究方法等问题,目前还不能为国际社会所普遍接受。
The withdrawal of state enterprises from health services and the country's accession to the WTO pose new challenges for both foreign and local pharmaceutical and health companies.While opportunities for capturing consumens and gaining market share emerge,companies face demands in intellectual proplerty and the need to continue to innovate.What is the new role of Pharmaceuticals in this changing health market?How can foreign pharmaceutical companies operate in a market that struggles with basic intellectural property issues ?Can private health services prosper in a market that has yet to prove it can pay?What is the potential of traditional and alternative medicine in China?
出处
《中国外资》
2000年第6期33-34,共2页
Foreign Investment in China
